JUBLPHARMA1,026.00

Jubilant Pharmova Ltd.

· Pharma & Health
₹ CrorePeersGLANDPPLPHARMAKIMSINDGNONESOURCEGRANULESPFIZERPOLYMEDMcap ₹16,211 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt3,414.12,436.93,219.53,219.5
Net Debt2,457.71,348.61,952.41,952.4
Total Debt/Equity0.630.390.450.45
Net Debt/Equity0.450.220.280.28
Total Debt/EBITDA3.792.082.562.56
Net Debt/EBITDA2.731.151.551.60
Interest Coverage (EBIT/Interest)1.913.353.873.87
Total Debt/Total Capital %38.6428.0931.2131.21
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.